Polyacetal-stilbene conjugates - The first examples of polymer therapeutics for the inhibition of HIF-1 in the treatment of solid tumours

Journal of Controlled Release

Volumn 164, Issue 3, 2012, Pages 314-322

  England, Richard M ^a   Masiá, Esther ^a   Giménez, Vanessa ^a   Lucas, Rut ^a,b   Vicent, María J ^a  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Cancer; Hypoxia inducible factor (HIF); pH Dependent degradation; Polyacetals; Polymer therapeutics

Indexed keywords

ACID CATALYST; ACID CONDITIONS; BISPHENOL A; BLOOD PLASMA; CANCER; CELL PROCESS; CELL TOXICITY; DIENESTROL; DIVINYL ETHER; DRUG LOADING; ENDOSOMES; EXTRACELLULAR FLUID; HEXESTROL; HIGH YIELD; HYPOXIA-INDUCIBLE FACTORS; LOW OXYGEN; OESTROGENS; PH-DEPENDENT; POLYMER THERAPEUTICS; STRUCTURAL SIMILARITY; SYNTHESIS STRATEGY; THERAPEUTIC INDEX; TUMOUR CELLS; WATERSOLUBLE POLYMERS;

ACETAL RESINS; BUTADIENE; ETHERS; ETHYLENE GLYCOL; MOLECULES; OLEFINS; PLASTIC PRODUCTS; POLYDISPERSITY; POLYETHYLENE GLYCOLS; SYNTHESIS (CHEMICAL); TRANSCRIPTION FACTORS; TUMORS;

FUNCTIONAL POLYMERS;

4,4' ISOPROPYLIDENEDIPHENOL; DIENESTROL; DIETHYLSTILBESTROL; HEXESTROL; HYPOXIA INDUCIBLE FACTOR 1; MACROGOL; POLYACETAL; POLYMER; UNCLASSIFIED DRUG;

ACIDITY; CATALYST; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOSOME; EXTRACELLULAR FLUID; FEMALE; HUMAN; HUMAN CELL; LYSOSOME; MOLECULAR WEIGHT; PRIORITY JOURNAL; SOLID TUMOR; SOLUBILITY;

ACETALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL HYPOXIA; CELL SURVIVAL; DRUG STABILITY; GENES, REPORTER; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; POLYMERS; SOLUBILITY; STILBENES;

EID: 84870249598     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.08.017     Document Type: Conference Paper

References (32)

1. G.L. Semenza Targeting HIF-1 for cancer therapy Nat. Rev. Cancer 3 10 2003 721 732
2. J. Pouyssegur, F. Dayan, and N.M. Mazure Hypoxia signalling in cancer and approaches to enforce tumour regression Nature 441 7092 2006 437 443
3. X. Lu, and Y. Kang Hypoxia and hypoxia-inducible factors: master regulators of metastasis Clin. Cancer Res. 16 24 2010 5928 5935
4. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat. Rev. Cancer 11 6 2011 393 410
5. G.L. Semenza Evaluation of HIF-1 inhibitors as anticancer agents Drug Discov. Today 12 19-20 2007 853 859
6. G.L. Semenza Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 29 5 2010 625 634
7. D.G. Nagle, and Y.D. Zhou Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1) Curr. Drug Targets 7 3 2006 355 369
8. R. Wang, S. Zhou, and S. Li Cancer therapeutic agents targeting hypoxia-inducible factor-1 Curr. Med. Chem. 18 21 2011 3168 3189
9. A. Giaccia, B.G. Siim, and R.S. Johnson HIF-1 as a target for drug development Nat. Rev. Drug Discov. 2 10 2003 803 811
10. R. Duncan Polymer therapeutics as nanomedicines: new perspectives Curr. Opin. Biotechnol. 22 4 2011 492 501
11. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 5 2003 347 360
12. P.K. Dhal, S.C. Polomoscanik, L.Z. Avila, S.R. Holmes-Farley, and R.J. Miller Functional polymers as therapeutic agents: concept to market place Adv. Drug Deliv. Rev. 61 13 2009 1121 1130
13. F.M. Veronese PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Verlag Basel
14. A.D. Keefe, S. Pai, and A. Ellington Aptamers as therapeutics Nat. Rev. Drug Discov. 9 7 2010 537 550
15. F. Canal, J. Sanchis, and M.J. Vicent Polymer-drug conjugates as nano-sized medicines Curr. Opin. Biotechnol. 22 6 2011 894 900
16. R. Webster, V. Elliot, B.K. Park, and D. Walker PEG and PEG conjugate toxicity: towards an understanding of toxicity of PEG and its relevance to pegylated biologicals F.M. Veronese, In PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Springer 127 146
17. F. Greco, and M.J. Vicent Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Deliv. Rev. 61 13 2009 1203 1213
18. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat. Rev. Cancer 2 1 2002 38 47
19. S. Chintela, K. Toth, S. Cao, F. Durrani, M. Vaughan, R. Jensen, and Y. Rustum Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha Cancer Chemother. Pharmacol. 66 5 2010 899 911
20. J. Sanchis, F. Canal, R. Lucas, and M.J. Vicent Polymer-drug conjugates for novel molecular targets Nanomedicine 5 6 2010 915 935
21. R. Tomlinson, M. Klee, S. Garrett, J. Heller, R. Duncan, and S. Brocchini Pendent chain functionalized polyacetals that display pH-dependent degradation: a platform for the development of novel polymer therapeutics Macromolecules 35 2 2002 473 480
22. J. Heller, D.W.H. Penhale, and R.F. Helwing Preparation of polyacetals by the reaction of divinyl ethers and polyols J. Polym. Sci. C Polym. Lett. 18 4 1980 293 297
23. M.J. Vicent, R. Tomlinson, S. Brocchini, and R. Duncan Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation J. Drug Target. 12 8 2004 491 501
24. V. Giménez, C. James, A. Armiñán, R. Schweins, A. Paul, and M.J. Vicent Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: diethylstilbestrol (DES)-polyacetals as prostate cancer treatment J. Control. Release 159 2 2012 290 301
25. R. Tomlinson, J. Heller, S. Brocchini, and R. Duncan Polyacetal- doxorubicin conjugates designed for pH-dependent degradation Bioconjugate Chem. 14 6 2003 1096 1106
26. A. Ao, H. Wang, S. Kamarajugadda, and J. Lu Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors Proc. Natl. Acad. Sci. U. S. A. 105 22 2008 7821 7826
27. T. Kubo, N. Maezawa, M. Osada, S. Katsumura, Y. Funae, and S. Imaoka Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1alpha (HIF-1alpha): structural requirement of bisphenol A for degradation of HIF-1alpha Biochem. Biophys. Res. Commun. 318 4 2004 1006 1011
28. V. Moreno-Manzano, F.J. Rodriguez-Jimenez, J.L. Acena-Bonilla, S. Fustero-Lardies, S. Erceg, J. Dopazo, D. Montaner, M. Stojkovic, and J.M. Sanchez-Puelles FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status J. Biol. Chem. 285 2 2010 1333 1342
29. H.D. Tang, C.J. Murphy, B. Zhang, Y.Q. Shen, E.A. Van Kirk, W.J. Murdoch, and M. Radosz Curcumin polymers as anticancer conjugates Biomaterials 31 27 2010 7139 7149
30. P. Deepa, S. Vasndhana, U. Jayanthi, and S. Krishnakumar Therapeutics and toxicologic evaluation of anti-lipogenic agents in cancer cells compared with non-neoplastic cells Basic Clin. Pharmacol. Toxicol. 110 6 2012 494 503
31. L. del Peso, M.C. Castellanos, E. Temes, S. Martin-Puig, Y. Cuevas, G. Olmos, and M.O. Landazuri The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen J. Biol. Chem. 278 49 2003 48690 48695
32. H. Högel, K. Rantanen, T. Jokilehto, R. Grenman, and P. Jaakkola Prolyl Hydrolase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells PLoS One 6 11 2011 e27112